PVT1 and diabetic kidney disease: Compared to the CTL-Cre+/Pvt1+/+ mice, STZ-treated Cre+/Pvt1+/+ (STZ-Cre+/Pvt1+/+) mice showed decreased body weight at 6 weeks, 8 weeks, 12 weeks and 20 weeks after DKD initiation, while the STZ-Cre+/Pvt1flox/flox mice showed less reduction of body weight at 20 weeks after DKD initiation compared to STZ-Cre+/Pvt1+/+ mice (Fig. 2A).